|Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis|
AJ Templeton, MG McNamara, B Šeruga, FE Vera-Badillo, P Aneja, ...
JNCI: Journal of the National Cancer Institute 106 (6), 2014
|Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis|
AJ Templeton, O Ace, MG McNamara, M Al-Mubarak, FE Vera-Badillo, ...
Cancer Epidemiology and Prevention Biomarkers 23 (7), 1204-1212, 2014
|Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis|
FE Vera-Badillo, AJ Templeton, P de Gouveia, I Diaz-Padilla, PL Bedard, ...
Journal of the National Cancer Institute 106 (1), djt319, 2013
|HER3 overexpression and survival in solid tumors: a meta-analysis|
A Ocana, F Vera-Badillo, B Seruga, A Templeton, A Pandiella, E Amir
JNCI: Journal of the National Cancer Institute 105 (4), 266-273, 2012
|Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial|
I Boutron, DG Altman, S Hopewell, F Vera-Badillo, I Tannock, P Ravaud
Journal of Clinical Oncology 32 (36), 4120-4126, 2014
|Simple prognostic score for metastatic castration‐resistant prostate cancer with incorporation of neutrophil‐to‐lymphocyte ratio|
AJ Templeton, C Pezaro, A Omlin, MG McNamara, R Leibowitz‐Amit, ...
Cancer 120 (21), 3346-3352, 2014
|Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis|
A Ocana, F Vera-Badillo, M Al-Mubarak, AJ Templeton, ...
PloS one 9 (4), e95219, 2014
|Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer|
FE Vera-Badillo, R Shapiro, A Ocana, E Amir, IF Tannock
Annals of oncology 24 (5), 1238-1244, 2013
|Systemic therapy for non–clear cell renal cell carcinomas: a systematic review and meta-analysis|
FE Vera-Badillo, AJ Templeton, I Duran, A Ocana, P de Gouveia, P Aneja, ...
European urology 67 (4), 740-749, 2015
|Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of …|
AJ Templeton, FE Vera-Badillo, L Wang, M Attalla, P De Gouveia, ...
Annals of oncology 24 (12), 2972-2977, 2013
|Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions|
A Ocaña, E Amir, F Vera, EA Eisenhauer, IF Tannock
Journal of Clinical Oncology 29 (3), 254, 2011
|Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two …|
RJ Van Soest, AJ Templeton, FE Vera-Badillo, F Mercier, G Sonpavde, ...
Annals of Oncology 26 (4), 743-749, 2014
|Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer|
R Leibowitz-Amit, AJ Templeton, A Omlin, C Pezaro, EG Atenafu, ...
Annals of oncology 25 (3), 657-662, 2014
|Chromophobe renal cell carcinoma: a review of an uncommon entity|
FE Vera‐Badillo, E Conde, I Duran
International Journal of Urology 19 (10), 894-900, 2012
|Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis|
FE Vera-Badillo, M Napoleone, A Ocana, AJ Templeton, B Seruga, ...
Breast cancer research and treatment 146 (2), 235-244, 2014
|Enzalutamide with standard first-line therapy in metastatic prostate cancer|
ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ...
New England Journal of Medicine 381 (2), 121-131, 2019
|Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis|
S Niraula, E Amir, F Vera-Badillo, B Seruga, A Ocana, IF Tannock
Journal of Clinical Oncology 32 (32), 3634-3642, 2014
|Relevance of randomised controlled trials in oncology|
IF Tannock, E Amir, CM Booth, S Niraula, A Ocana, B Seruga, ...
The Lancet Oncology 17 (12), e560-e567, 2016
|Fulvestrant for advanced breast cancer: a meta-analysis|
M Al-Mubarak, AG Sacher, A Ocana, F Vera-Badillo, B Seruga, E Amir
Cancer treatment reviews 39 (7), 753-758, 2013
|Benefit and harms of new anti-cancer drugs|
FE Vera-Badillo, M Al-Mubarak, AJ Templeton, E Amir
Current oncology reports 15 (3), 270-275, 2013